TTP is a hematologic emergency that demands immediate recognition and treatment to prevent fatal outcomes. In this HemeTalks episode, Dr. Yazan Abou-Ismail and Dr. Kolton Smith discuss the diagnostic hallmarks, therapeutic advances, and follow-up strategies for patients with TTP.

Through the lens of a clinical case, they explore the impact of caplacizumab, the importance of ADAMTS13 testing, and how to differentiate TTP from other TMAs. Tune in for practical insights that every hematologist and frontline provider should know.

Learning Objectives:

1. Recognize clinical and laboratory features indicative of TTP.
2. Understand the evolving treatment landscape, including the role of caplacizumab.
3. Apply principles for acute and chronic management of both congenital and acquired TTP.

Clinical Pearls:

1. Always consider iTTP diagnosis in any patient with findings of thrombotic microangiopathy, as early recognition is critical.
2. When iTTP is suspected, it is essential to start empiric therapy immediately—untreated disease carries a high mortality risk.
3. Monitor closely for disease exacerbation or relapse even after initial clinical response is achieved.